D&D Pharmatech Inc. (KOSDAQ:347850)
South Korea · Delayed Price · Currency is KRW 277,000
+55,000 (24.77%)
Oct 31, 2025, 1:40 PM KST
D&D Pharmatech Revenue
D&D Pharmatech had revenue of 924.56M KRW in the quarter ending June 30, 2025, a decrease of -60.09%. This brings the company's revenue in the last twelve months to 9.33B, down -29.52% year-over-year. In the year 2024, D&D Pharmatech had annual revenue of 11.44B, down -38.77%.
Revenue (ttm)
9.33B
Revenue Growth
-29.52%
P/S Ratio
258.23
Revenue / Employee
444.44M
Employees
21
Market Cap
2.41T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.44B | -7.24B | -38.77% |
| Dec 31, 2023 | 18.68B | 18.07B | 2,958.97% |
| Dec 31, 2022 | 610.57M | -753.54M | -55.24% |
| Dec 31, 2021 | 1.36B | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |